Article Text

OC-65 Hemophagocytic lymphohistiocytosis – the importance of an earlier diagnosis and treatment in paediatric practice
  1. Mihaela Bataneant1,2,
  2. Cristian Jinca1,2,
  3. Mihaela Baica2,
  4. Estera Boeriu1,2,
  5. Patricia Urtila1,2,
  6. Mihaela Popa Serb2,
  7. Smaranda Arghirescu1,2,
  8. Anca Popoiu1,2,
  9. Carmen Petrescu1,2,
  10. Maria Cucuruz2,
  11. Margit Serban2
  1. 1University of Medicine and Pharmacy “Victor Babes” Timisoara, Romania
  2. 2Clinical Emergency Hospital for Children “Louis Turcanu”, IIIrd Paediatric Clinic, Timisoara, Romania


Introduction Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome, its diagnosis being based on fulfilment of five out of eight clinical and laboratory parameters (fever, splenomegaly, cytopenia, hemophagocytosis, ferritin>500 ng/ml, hypertrygliceridemia and/or hypofibrinogenemia, low or absent NK cell activity, increased of soluble receptor for IL2) or a molecular diagnosis of a disease conferring a high risk of developing HLH. The differentiation between primary and secondary HLH (infections, autoimmune and metabolic diseases, malignancy) is very important for treatment decision.

Aim To identify the cause of HLH, clinical and laboratory parameters, to analyse the treatment and the evolution.

Material and method 13 patients between 2 months and 8 years of age were diagnosed based on mentioned criteria (at least 5 of 8 ) with HLH in the period 1995–2017.

Results 6 of them (46%) had primary HLH (1 Griscelli and 1Chediak-Higashi syndrome, 1 case FHLH2 and 3 cases with probability of FHLH) and 7 (54%) had secondary HLH (2 cases with leishmaniosis, 2 EBV induced, 1 BCG-itis, 1 Kawasaki and 1 leukaemia). HLH 2004 protocol treatment (dexamethasone, etoposide, cyclosporine) was used in 8 patients (61%) – in 5 cases complete schema and in 3 cases partial treatment. One patient was bone marrow transplanted. The mortality rate was 53,7%, 4/6 (66,6%) in primary HLH and 3/7 (42,8%) in secondary HLH. Also the mortality rate was 60% in patients not HLH treated, 60% in patients with complete schema and 66,6% in patients with partial schema.

Conclusions HLH is a potential fatal syndrome sometimes with fulminant evolution, an earlier diagnosis being crucial for an earlier treatment. In secondary HLH the etiologic treatment is often insufficient, needing also HLH treatment for life saving. In primary HLH bone marrow transplantation is the curative treatment, HLH protocol being obligatory but insufficient for survival.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.